利拉鲁肽治疗冠心病合并2型糖尿病患者的临床研究  

Clinical study of liraglutide in the treatment of coronary heart disease with type 2 diabetes mellitus

作　　者：李晓静[1] LI Xiao-jing(Dalian Central Hospital,Dalian 116000,China)

机构地区：[1]大连市中心医院,116000

出　　处：《中国实用医药》2024年第6期93-95,共3页China Practical Medicine

摘　　要：目的 分析利拉鲁肽治疗冠心病合并2型糖尿病患者的临床效果。方法 102例冠心病合并2型糖尿病患者,应用电脑随机选择方式将患者分为对照组和观察组,每组51例。对照组给予二甲双胍治疗,观察组给予二甲双胍结合利拉鲁肽治疗。对比两组心功能指标(左室射血分数、左室舒张末内径、心排血量以及QT离散度)、血糖指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、胰岛素抵抗情况[胰岛β细胞功能指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)]。结果 治疗后,观察组左室射血分数(56.10±9.06)%、左室舒张末内径(45.80±6.64)mm、心排血量(5.60±1.18)L/min、QT离散度(45.03±6.31)ms优于对照组的(50.50±7.90)%、(50.20±7.07)mm、(4.88±1.01)L/min、(53.77±8.50)ms(P<0.05)。治疗后,观察组2 h PG(7.28±1.30)mmol/L、FPG(6.06±0.27)mmol/L、HbA1c(5.88±0.32)%优于对照组的(8.71±1.20)mmol/L、(7.01±0.76)mmol/L、(6.65±0.52)%(P<0.05)。治疗后,观察组HOMA-β、HOMA-IR优于对照组(P<0.05)。结论 结合冠心病合并2型糖尿病患者实际情况应用二甲双胍结合利拉鲁肽治疗,能够有效改善患者的心功能指标、血糖指标及胰岛素抵抗情况,具有优良的应用前景,在今后的工作过程中能够进一步应用。Objective To analyze the clinical effect of liraglutide in the treatment of coronary heart disease with type 2 diabetes mellitus.Methods 102 patients with coronary heart disease and type 2 diabetes mellitus were divided into a control group and an observation group according to computer random grouping method.The control group was treated with metformin,and the observation group was treated with metformin and liraglutide.Both groups were compared in terms of cardiac function indicators(left ventricular ejection fraction,left ventricular end-diastolic diameter,cardiac output and QT dispersion),blood glucose indicators[fasting plasma glucose(FPG),2 h postprandial glucose(2 h PG),glycosylated hemoglobin(HbA1c),homeostasis model assessment of insulin resistance(HOMA-IR),β-cell function(HOMA-β)].Results After treatment,the observation group had left ventricular ejection fraction of(56.10±9.06)%,left ventricular end-diastolic diameter of(45.80±6.64)mm,cardiac output of(5.60±1.18)L/min,and QT dispersion of(45.03±6.31)ms,which were better than(50.50±7.90)%,(50.20±7.07)mm,(4.88±1.01)L/min,and(53.77±8.50)ms in the control group(P<0.05).After treatment,the observation group had 2 h PG of(7.28±1.30)mmol/L,FPG of(6.06±0.27)mmol/L and HbA1c of(5.88±0.32)%,which were better than(8.71±1.20)mmol/L,(7.01±0.76)mmol/L and(6.65±0.52)%in the control group(P<0.05).After treatment,the observation group had HOMA-βand HOMA-IR was better than the control group(P<0.05).Conclusion The combination of metformin and liraglutide can effectively improve the patients'cardiac function indicators,blood glucose indicators and insulin resistance status,suggesting that this type of treatment model has excellent application prospects and can be further applied in future work processes.

关 键 词：利拉鲁肽 冠心病 2型糖尿病 心功能指标 血糖指标 胰岛素抵抗 

分 类 号：R587.1[医药卫生—内分泌] R541.4[医药卫生—内科学]